Oncotype DX GPS 指导早期前列腺癌治疗决策的成本效果
本研究用 Markov 模型模拟 65 岁极低危、低危或有利中危前列腺癌患者接受主动监测或立即治疗,比较 GPS 指导与无检测策略的 20 年结局。总体 ICER 为每 QALY 31394 美元,各风险组均具成本效果,但对主动监测与无疾病证据状态的效用值敏感。
要点
- GPS 指导治疗决策总体 ICER 为每 QALY 31394 美元。
- 极低危、低危、有利中危组 ICER 分别为 25343、28911、39695 美元/QALY。
- 成本效果对主动监测效用值和无疾病证据状态效用值的小差异敏感。
核心结论
- GPS 用于指导主动监测与立即治疗决策具有成本效果。
- 成本效果对主动监测和无疾病证据状态效用值的小差异敏感,需重视患者偏好评估。
研究设计与样本
- Markov 模型模拟 65 岁极低危、低危或有利中危前列腺癌患者 20 年结局,比较 GPS 指导与无检测下的主动监测或立即治疗。
- 效用、成本和概率取自文献与国家 Medicare 费用表,从支付方角度计算增量成本效果比(ICER)。
主要发现
- 总体队列 GPS 指导治疗的 ICER 为每 QALY 31394 美元。
- 极低危组 ICER 为每 QALY 25343 美元。
- 低危组 ICER 为每 QALY 28911 美元。
- 有利中危组 ICER 为每 QALY 39695 美元。
- 敏感性分析显示,在每 QALY 100000 美元支付意愿下,结果对关键模型参数变化稳健。
关键数值与推荐
- GPS 为 17 基因表达检测,用于辅助主动监测与立即治疗决策。
- 总体 ICER 为每 QALY 31394 美元。
- 极低危、低危、有利中危组 ICER 分别为每 QALY 25343、28911、39695 美元。
- 结果对主动监测年管理成本、退出主动监测转治疗概率、治疗成本、治疗后生化失败概率等参数变化稳健。
临床怎么用
- GPS 可辅助 65 岁极低危至有利中危前列腺癌患者在选择主动监测或立即治疗时进行成本效果决策。
- 临床决策中应结合患者对主动监测和无疾病证据状态的偏好进行评估。
局限性
- 成本效果对主动监测效用值和无疾病证据状态效用值的小差异敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the cost-effectiveness of using the Oncotype DX Genomic Prostate Score (GPS), a 17-gene expression assay that can be used to inform decisions regarding active surveillance (AS) vs immediate treatment. METHODS: We developed a Markov model simulating 20-year outcomes for 65-year-old men with very low-, low-, or favorable intermediate-risk prostate cancer undergoing AS vs immediate treatment using GPS vs no testing. Utilities, costs, and probabilities were extracted from the literature and National Medicare Fee Schedules to determine incremental cost-effectiveness ratios (ICER) from a payer perspective. RESULTS: In the overall cohort, the ICER of GPS-guided therapy was $31,394 per quality-adjusted life-year (QALY). When stratified by risk group, the ICER was $25,343 per QALY in very low-risk, $28,911 per QALY in low-risk, and $39,695 per QALY in favorable intermediate-risk patients. On sensitivity analysis, findings were robust against a willingness-to-pay of $100,000 per QALY to variations in key model parameters, including the cost of annual management of AS, probability of exiting AS to treatment, cost of treatment, and probability of biochemical failure post-treatment. However, the cost-effectiveness was sensitive to small differences in the utility of AS and the utility of no evidence of disease post-treatment states. CONCLUSION: The use of the GPS was cost-effective in guiding treatment decisions regarding AS vs immediate treatment. The cost-effectiveness was sensitive to small differences in the utilities of the AS and no evidence of disease post-treatment states, highlighting the importance of assessing patient preferences.
引用
- Chang EM, Punglia RS, Steinberg ML, et al. Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer. Urology. 2018. PMID: 30580007. doi:10.1016/j.urology.2018.12.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。